IUX24
TopMarketWorldEconomyFinanceTechnologyBusinessPoliticsAnalysis & Opinion

Rezera Launches US IPO Seeking Up to $217 Million

Boston-based drug developer Rezera has launched its US initial public offering roadshow, seeking up to 216.7 million dollars. The biotech firm plans to list on the Nasdaq under the symbol RZRA.

Xurve View
Insights:
FILE PHOTO: A street sign for Wall Street is seen outside the New York Stock Exchange (NYSE) in New York City, New York, U.S., July 19, 2021. REUTERS/Andrew Kelly/File Photo

Drug developer Rezera launched its United States IPO roadshow on Thursday, seeking up to $216.7 million by offering 16.7 million shares priced between $11 and $13. The offering adds to a rush of biotech firms tapping the fall IPO window. At the top of the marketed range, Rezera would fetch a $270 million valuation.